Cholera-Hospital-Based-Intervention-for-7-days

checkorphan
Learn more about:
Cholera
Related Clinical Trial
First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131). Immune Response to a Delayed Second Dose of Oral Cholera Vaccine Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Cholera-Hospital-Based-Intervention-for-7-days

Official Title

CHoBI7 Trial: A Hospital Based Water, Sanitation and Hygiene Intervention for Households of Diarrheal Patients in Bangladesh

Brief Summary

      The Cholera Hospital Based Intervention for 7 Days (CHoBI7) randomized controlled trial for
      transition to scale aimed to: (1) Develop and evaluate scalable approaches to integrate the
      CHoBI7 intervention into the services provided for hospitalized diarrhea patients at health
      facilities in Bangladesh; and (2) Evaluate the ability of the CHoBI7 intervention to lead to
      a sustained uptake of the promoted hand washing with soap and water treatment behaviors and
      significant reductions in diarrheal disease over time.

Detailed Description

      The findings from the recent randomized controlled trial of The Cholera Hospital Based
      Intervention for 7 Days (CHoBI7) demonstrated that this intervention was effective in
      significantly reducing symptomatic cholera infections in intervention households, and had
      significant sustained impacts on hand washing with soap behaviors and improved water quality
      12 months post intervention. Next steps to transition to scale were: (1) Develop and evaluate
      scalable approaches to integrate the CHoBI7 intervention into the services provided for
      hospitalized diarrhea patients at health facilities in Bangladesh; and (2) Evaluate the
      ability of the CHoBI7 intervention to lead to a sustained uptake of the promoted hand washing
      with soap and water treatment behaviors and significant reductions in diarrheal disease over
      time.

Study Type

Interventional

Primary Outcome

Diarrhea prevalence among children under 2 years of age

Secondary Outcome

 Diarrhea prevalence among participants ages 5-9 years

Condition

Cholera

Intervention

CHoBI7 health facility program

Study Arms / Comparison Groups

 Standard recommendation (ORS)
Description:  Participants received the standard recommendation on oral rehydration solution use

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Behavioral

Estimated Enrollment

2626

Start Date

December 4, 2016

Completion Date

April 26, 2019

Primary Completion Date

April 26, 2019

Eligibility Criteria

        Inclusion Criteria:

        Diarrhea patients will be defined as patients having acute watery diarrhea three or more
        loose stools over a 24-hour period in the past three days. Diarrhea patients admitted to
        ICDDRB Dhaka Hospital or Mugda General Hospital will be eligible for the trial if:

          1. have had 3 or more loose stools over the past 24 hours

          2. plan to reside in Dhaka for the next 12 months

          3. have no basin for running water in their home

          4. have a child under five years of age in their household (including themselves) that
             produced a stool sample at baseline

          5. have a working mobile phone in the household.

        Household members of the diarrhea patient will be eligible for the trial if:

          1. they have shared the same cooking pot and resided in the same home with the diarrhea
             patient for the last three days

          2. plan to reside in their current household with the diarrhea patient for the next 12
             months

        Exclusion Criteria:

        (1) Children in foster care will be excluded from all research study activities.

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Christine Marie George, PhD, ,

Administrative Informations

NCT ID

NCT04008134

Organization ID

IRB00006785

Secondary IDs

PR-15133

Responsible Party

Sponsor

Study Sponsor

Johns Hopkins Bloomberg School of Public Health

Collaborators

 International Centre for Diarrhoeal Disease Research, Bangladesh

Study Sponsor

Christine Marie George, PhD, Principal Investigator, Johns Hopkins Bloomberg School of Public Health

Verification Date

January 2022